• Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World
Newsy Today
news of today
Home - hormone therapy
Tag:

hormone therapy

Health

Can Birth Control Cause Binge Eating?

by Chief Editor June 19, 2026
written by Chief Editor

Monophasic combined oral contraceptives may trigger emotional eating and binge eating episodes, according to a prospective cohort study published in JAMA Network Open. Researchers at Michigan State University found that women using these pills reported more frequent binge-related behaviors during the 21 days of active hormone intake compared to the seven days of inactive reminder pills. This effect occurred regardless of whether the participants had a pre-existing Binge Eating Disorder diagnosis.

Why does the combined pill influence eating behavior?

The study, led by Dr. Kelley Klump, indicates that the hormonal stability provided by the combined pill mimics the body’s mid-luteal phase for three out of every four weeks. During a natural menstrual cycle, women typically experience higher progesterone and estrogen levels only for a short window. By artificially maintaining these levels with monophasic pills, women are kept in a state that researchers associate with an increased risk of binge eating. According to the team at Michigan State University, this behavior is linked directly to the synthetic hormone levels rather than mood swings or negative body image.

Did you know?

The study utilized the Michigan State University Twin Registry to track 422 participants. This approach allowed researchers to isolate the effects of synthetic hormones while controlling for genetic and environmental variables that often complicate appetite research.

How did researchers measure binge eating?

To determine if the pill caused these behavioral changes, the research team asked volunteers aged 15 to 30 to complete nightly surveys for 49 days. Participants tracked their mood, weight preoccupation, and emotional eating incidents across two pill cycles. By comparing active pill days (days 1–21) to inactive pill days (days 22–28), the team found a consistent pattern of increased emotional eating during hormone-active periods. The data indicated that these episodes were not driven by negative affect or body dissatisfaction, distancing the behavior from traditional psychological triggers.

View this post on Instagram about Binge Eating Disorder, Network Open
From Instagram — related to Binge Eating Disorder, Network Open

Future trends in hormonal health and nutrition

As awareness grows regarding the link between endocrine function and eating patterns, clinical practices are expected to shift toward more personalized contraceptive counseling. Future research may focus on whether multiphasic pills—which change hormone doses throughout the cycle—or progestin-only “mini-pills” offer a different risk profile for those prone to binge eating. Clinicians are increasingly encouraged to look beyond typical side effects like nausea or spotting and consider how a patient’s chosen birth control may interact with their metabolic and eating health.

Brain over Binge Podcast Ep. 186: Biology of Binge Eating: Research on Leptin & GLP-1 (Pamela Keel)

Pro Tip: Managing your birth control conversation

If you suspect your current birth control is affecting your appetite, keep a 30-day log of your eating habits and mood. Bring this data to your primary care physician or gynecologist. They can help you compare your current monophasic pill against alternatives like the mini-pill or non-hormonal options.

Frequently Asked Questions

Does the pill cause Binge Eating Disorder?

The study suggests the combined pill can trigger episodes of emotional and binge eating in both those with and without a formal Binge Eating Disorder diagnosis. It does not suggest the pill creates the disorder itself, but rather exacerbates the behavioral symptoms.

Should I stop taking my birth control immediately?

No. Experts, including those involved in the study, advise against stopping medication without consulting a doctor. Monophasic pills are effective for many conditions, including acne and endometriosis, and individual responses to hormones vary significantly.

Are there birth control options that don’t affect appetite?

Every hormonal method carries different metabolic profiles. Options like the progestin-only pill (mini-pill) or different formulations of combined pills may affect your system differently. Discussing your specific history with a healthcare provider is the safest way to find an alternative.


Have you noticed changes in your appetite since starting a new contraceptive? Join the discussion below or subscribe to our health bulletin for the latest updates on medical research and women’s health.

June 19, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Gene Test Identifies Breast Cancer Patients Who Can Safely Skip Chemotherapy

by Chief Editor June 9, 2026
written by Chief Editor

A genomic test can identify many breast cancer patients who can safely forgo chemotherapy without increasing their risk of recurrence, according to results from the international OPTIMA trial presented at the 2026 American Society of Clinical Oncology meeting. Researchers found that patients aged 40 and over with hormone-sensitive tumors and a low Prosigna test score achieved five-year survival rates comparable to those who received chemotherapy, effectively sparing thousands of patients from unnecessary treatment-related toxicity.

How does the Prosigna test determine treatment?

The Prosigna test measures the activity of genes involved in breast cancer growth using tissue samples from surgery or diagnostic biopsies, according to the OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis) research team. By analyzing these biological markers, clinicians can distinguish between tumors that require aggressive systemic treatment and those that respond sufficiently to hormone therapy alone. Lead investigator Professor Rob Stein of the University College London Cancer Institute states that the test allows medical teams to shift away from relying solely on traditional clinical features, such as tumor size or lymph node involvement, toward a model driven by tumor biology.

How does the Prosigna test determine treatment?
Did you know?
The OPTIMA trial included 4,429 patients across the UK, Norway, Sweden, Australia, New Zealand, and Thailand. Unlike previous studies that focused heavily on postmenopausal women with limited lymph node involvement, this trial included premenopausal women and those with more extensive disease.

What were the survival outcomes for patients?

Data from the trial shows that 68% of participants received a low Prosigna score, indicating a low risk of recurrence. For this specific group, the five-year survival rate was 94.9% for those who received chemotherapy and 95.1% for those who did not. According to the study’s statistical analysis, at most 2% of patients with a low score would see any benefit from chemotherapy, suggesting the treatment provides little to no additional protection for the vast majority of this population. Professor Iain MacPherson of the University of Glasgow notes that these findings provide robust, practice-changing evidence that chemotherapy use can be safely reduced.

What were the survival outcomes for patients?

Case Study: A patient’s experience with genomic testing

Karen Bonham, a 64-year-old speech and language therapist from Cardiff, was diagnosed with hormone-sensitive breast cancer in 2017. Despite standard clinical guidelines suggesting chemotherapy for her specific diagnosis—which included two affected lymph nodes—the Prosigna test results arrived just days before her scheduled treatment. Because her test indicated a low score, Bonham was assigned to the trial’s test-directed group. She avoided chemotherapy entirely, opting instead for radiotherapy and hormone therapy. Almost nine years later, Bonham remains cancer-free, attributing her quality of life to the ability to receive targeted, appropriate treatment rather than a one-size-fits-all regimen.

The OPTIMA Clinical Trial

What is the future of genomic testing in the NHS?

Healthcare bodies, including the National Institute for Health and Care Excellence (NICE), are expected to use these findings to evaluate wider access to Prosigna testing. By demonstrating the cost-effectiveness of test-directed treatment, the trial provides a pathway for the National Health Service (NHS) to reduce unnecessary chemotherapy for an estimated 5,000 patients annually. While the current results are comprehensive, researchers noted that it is not yet known if these findings apply to patients under the age of 40. The next phase of the trial is designed to generate data specifically for this younger demographic.

Pro Tip:
If you or a loved one are facing a breast cancer diagnosis, ask your oncologist if genomic testing is appropriate for your specific tumor profile. Understanding the biological activity of the cancer can often help patients and doctors make more informed decisions about the necessity of systemic therapies.

Frequently Asked Questions

  • Who is eligible for the Prosigna test? The OPTIMA trial results apply to patients aged 40 and older with hormone-sensitive breast cancer.
  • Does the test work for patients with lymph node involvement? Yes. The trial successfully demonstrated that outcomes were similar regardless of the number of affected lymph nodes.
  • Is chemotherapy always necessary for breast cancer? No. According to the OPTIMA trial, many patients with low genomic scores can safely avoid chemotherapy without compromising their survival outcomes.

Have you or a family member been affected by breast cancer treatment decisions? Share your thoughts in the comments below or subscribe to our health newsletter for the latest updates on oncology research and personalized medicine.

June 9, 2026 0 comments
0 FacebookTwitterPinterestEmail

Recent Posts

  • Honda Riders Face Heatwave at Brno GP

    June 20, 2026
  • UK Developing New Missiles for Ukraine Without US Components

    June 20, 2026
  • Squadron 42: First Hands-On Press and Community Preview Begins

    June 20, 2026
  • Former Employee Sues High Plains Mental Health Over Alleged Disability Discrimination

    June 20, 2026
  • US Military Responds to Iran as 55 Ships Transit Strait of Hormuz

    June 20, 2026

Popular Posts

  • 1

    Maya Jama flaunts her taut midriff in a white crop top and denim jeans during holiday as she shares New York pub crawl story

    April 5, 2025
  • 2

    Saar-Unternehmen hoffen auf tiefgreifende Reformen

    March 26, 2025
  • 3

    Marta Daddato: vita e racconti tra YouTube e podcast

    April 7, 2025
  • 4

    Unlocking Success: Why the FPÖ Could Outperform Projections and Transform Austria’s Political Landscape

    April 26, 2025
  • 5

    Mecimapro Apologizes for DAY6 Concert Chaos: Understanding the Controversy

    May 6, 2025

Follow Me

Follow Me
  • Cookie Policy
  • CORRECTIONS POLICY
  • PRIVACY POLICY
  • TERMS OF SERVICE

Hosted by Byohosting – Most Recommended Web Hosting – for complains, abuse, advertising contact: o f f i c e @byohosting.com


Back To Top
Newsy Today
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World